ViiV Healthcare Says Health Canada Approved APRETUDE For Pre-Exposure Prophylaxis To Reduce Risk Of Sexually Acquired HIV
ViiV Healthcare Says Health Canada Approved APRETUDE For Pre-Exposure Prophylaxis To Reduce Risk Of Sexually Acquired HIV
**** Healthcare表示，加拿大卫生部批准了APRETUDE进行暴露前预防，以降低性获得性感染艾滋病毒的风险
- Approved for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV infection in at-risk adults and adolescents aged 12 years and older, weighing at least 35 kg, including men who have sex with men, transgender women, and cisgender women.
- APRETUDE (cabotegravir extended release injectable suspension) is the first and only long-acting injectable PrEP treatment approved in Canada.
- Given as few as six times per year after initiation and demonstrated superior efficacy to a daily oral PrEP option (FTC/TDF tablets) in reducing the risk of HIV acquisition in 2 clinical trials.1
- The latest Canadian surveillance data shows that there were 1,833 new HIV diagnoses in 2022, a 24.9 per cent increase from 2021.2
- 获准用于暴露前预防 (PrEP)，以降低年龄在 12 岁及以上、体重至少为 35 kg 的高危成人和青少年的性获得性 HIV 感染风险，包括与男性发生性关系的男性、变性女性和顺性别女性。
- APRETUDE（卡博特韦缓释注射悬浮液）是加拿大批准的第一种也是唯一一种长效可注射的PrEP疗法。
- 在两项临床试验中，启动后每年仅给药六次，在降低感染HIV风险方面，与每日口服PrEP方案（FTC/TDF片剂）相比，表现出优于每日口服PrEP方案（FTC/TDF片剂）的疗效。1
- 加拿大最新的监测数据显示，2022年新增了1,833例艾滋病毒诊断，比2021年增加了24.9％。2
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。